Anti-PD-L1 immunotherapy responsive in microsatellite-stable mCRC comb with MEK inhibition

Anti-PD-L1 immunotherapy may achieve a response in patients with microsatellite-stable metastatic colorectal cancer if combined with a MEK inhibitor, according to phase I data presented at the ESMO 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain. "So far, immunotherapy has only shown activity in patients with microsatellite instability-high colorectal cancer , which is only 5% of the population," says the study's principal investigator Dr Johanna Bendell, from the Sarah Cannon